Appendix 5 - SBUHB MM savings plan 2025-6

NICE High Cost Drugs - High Value Savings

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2025/26 (All Schemes)	Comment	Category		Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Total
May-24	Secondary Care	Natalizumab	Price reduction to originator product	£340,000	£28,333	1 month carryover	High Cost Drugs/ Nice	Projected Savings	£28,333												£28,333
								Actual Savings	£33,222												£33,222
Jul-24	Secondary Care	Pembrolizumab	Home Delivery and administration of Pembrolizumab	£24,000	£6,000	3 month carryover	High Cost Drugs/ Nice	Projected Savings	£2,000	£2,000	£2,000										£6,000
								Actual Savings	£1,885	£668	£2,004										£4,557
Oct-24	Secondary Care	Bevacizumab	Switch to biosimilar product - been unavailable	£60,000	£30,000	6 month carryover	High Cost Drugs/ Nice	Projected Savings	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000							£30,000
								Actual Savings	£0	£0	£0	£0	£0	£7,216							£7,216
Dec-24	Secondary Care	Dimethyl Fumarate	Generic switch from Tecfidera in MS	£309,400	£266,428	Incremental implementation	High Cost Drugs/ Nice	Projected Savings	£14,324	£18,621	£22,919	£25,783	£25,783	£25,783	£25,783	£25,783	£25,783	£21,486	£18,621	£15,756	£266,428
								Actual Savings	£41,099	£12,817	£41,224	£22,319	£0	£28,406	£34,493	£18,261					£198,619
Feb-25	Secondary Care	Infliximab	Change of biosimilar product from Inflectra (£80 per vial) to Flixabi (£55 per vial) in gastroenterology	£180,000	£150,000	10 month carryover	High Cost Drugs/ Nice	Projected Savings	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000			£150,000
								Actual Savings	£17,005	£16,195	£14,605	£17,786	£14,807	£16,744	£17,497	£15,617					£130,256
Oct-24	Secondary Care	Ustekinumab	Switch to biosimilar product when launched (Oct 2024). Gastro 49%; Derm 36%; Rheum 15%)	£1,260,000	£1,085,000	Incremental implementation	High Cost Drugs/ Nice	Projected Savings	£58,333	£75,833	£93,333	£105,000	£105,000	£105,000	£105,000	£105,000	£105,000	£87,500	£75,833	£64,167	£1,084,999
								Actual Savings	£80,274	£45,646	£136,938	£110,180	£25,184	£119,624	£153,692	£71,337					£742,875
Apr-25	Secondary Care	Thalidomide	Switch to generic product - currently unavailable	£60,000	£60,000	Apr 25 implementation	High Cost Drugs/ Nice	Projected Savings	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£60,000
								Actual Savings	£5,959	£4,334	£1,083	£0	£0	£2,167	£2,980	£6,230					£22,753
May-25	Secondary Care	Pomalidamide	Switch to generic product	£180,000	£165,000	May 25 implementation	High Cost Drugs/ Nice	Projected Savings		£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£165,000
								Actual Savings		£32,582	£32,582	£40,727	£39,954	£35,417	£35,991	£40,727					£257,980
Jun-25	Secondary Care	Bosutinib	Availability of generic product	£200,000	£166,667	June 25 impementation	High Cost Drugs/ Nice	Projected Savings			£16,667	£16,667	£16,667	£16,667	£16,667	£16,667	£16,667	£16,667	£16,667	£16,667	£166,667
								Actual Savings			£24,831	£10,483	£0	£13,668	£6,549	£15,495					£71,027
Jul-25	Secondary Care	Nilotinib	Availability of generic product	£40,000	£26,667	Stock available - using stock up	High Cost Drugs/ Nice	Projected Savings					£3,333	£3,333	£3,333	£3,333	£3,333	£3,333	£3,333	£3,333	£26,667
								Actual Savings					£3,167	£2,111	£1,583	£3,167					£10,028
Sep-25	Secondary Care	Tocilizumab	Switch to Tyenne sub-cuteneous IV (tocilizumab biosimilar) in rheumatology	£48,000	£24,000	Sep 25 implementation	High Cost Drugs/ Nice	Projected Savings							£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£24,000
								Actual Savings							£3,319	£3,614					£6,933
Sep-25	Secondary Care	Tocilizumab	Switch to Tyenne sub-cuteneous (tocilizumab biosimilar) in rheumatology	£180,000	£90,000	Need homecare establishment	High Cost Drugs/ Nice	Projected Savings						£0	£15,000	£15,000	£15,000	£15,000	£15,000	£15,000	£90,000
								Actual Savings						£1,014	£6,081	£9,291					£16,386
Jul-25	Secondary Care	Axitinib	Availability of generic product	£60,000	£40,000	Stock available - delay via homecare	High Cost Drugs/ Nice	Projected Savings								£0					£0
								Actual Savings								£0					£0
Oct-25	Secondary Care	Eltrombopag	Potential availability of generic product - contract in place from Oct-25	£280,000	£116,667	Awaiting generic availability - Oct 25	High Cost Drugs/ Nice	Projected Savings							£0	£19,444	£19,444	£19,444	£19,444	£19,444	£97,222
								Actual Savings							£8,103	£16,193					£24,296
Oct-25	Secondary Care	Omalizumab	Switch to biosimilar product	£90,000	£37,500	Awaiting biosimilar product launch/legal challenge	High Cost Drugs/ Nice	Projected Savings							£0	£3,125	£3,125	£3,125	£3,125	£3,125	£15,625
								Actual Savings							£356	£12,462					£12,818
Oct-25	Secondary Care	Fampridine	Potential availability of generic product (assuming 25% saving on current price paid)	£60,000	£30,000	Awaiting generic availability ?Oct25	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Dec-25	Secondary Care	Faricimab	All Wales contract price reduction and rebate	£480,000	£160,000	November contract change - Dec implementation	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Dec-25	Secondary Care	Aflibercept	All Wales contract price reduction on 8mg preparation			December contract change	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Feb-26	Secondary Care	Denosumab	Switch to biosimilar product (assuming 25% saving on current price paid)	£120,000	£20,000	Awaiting biosimilar product launch	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Feb-26	Secondary Care	Pazopanib	Potential availability of generic product (assuming 25% saving on current price paid)	£16,000	£2,667	Awaiting generic availability ?Aug 25	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Feb-26	Secondary Care	Aflibercept	Switch to biosimilar product	£780,000	£130,000	Awaiting biosimilar product launch/	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Feb-26	Secondary Care	Ferric Carboxymaltose	Switch to generic product (assuming 25% saving on current price paid)	£30,000	£5,000	Awaiting biosimilar product launch	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Feb-26	Secondary Care	Apremilast	Potential availability of generic product (assuming 25% saving on current price paid)	£24,000	£4,000	Awaiting generic availability ?Aug 25	High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
TOTAL				£4,821,400	£2,643,928			Monthly Savings	£179,444	£112,242	£253,267	£201,495	£83,112	£226,367	£270,644	£212,394	£0	£0	£0	£0	£1,538,966
								Projected Savings	£127,990	£136,454	£174,918	£187,450	£190,783	£190,783	£204,783	£227,353	£227,353	£205,556	£176,024	£161,493	£2,210,941
								Actual Savings	£179,444	£112,242	£253,267	£201,495	£83,112	£226,367	£270,644	£212,394	£0	£0	£0	£0	£1,538,966

Secondary Care Savings (Non-NICE/High-Cost)

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2025/26	Comment	Category		Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Total
Oct-24	Secondary Care	Melatonin liquid	Switch to Ceyesto	£36,000	£18,000	Moving to WP10HP?	Secondary Care	Projected Savings	£3,000	£3,000	£3,000	£3,000	£3,000	£3,000							£18,000
								Actual Savings	£1,124	£823	£179	£220	£212	£0							£2,558
Sep-24	Secondary Care	Fidaxomicin	Short term switch to liquid product for 25% saving	£24,000	£24,000		Secondary Care	Projected Savings						£6,000	£6,000	£6,000	£6,000				£24,000
								Actual Savings						£9,240	£7,560	£8,820					£25,620
TOTAL				£36,000	£18,000			Monthly Savings	£1,124	£823	£179	£220	£212	£9,240	£7,560	£8,820	£0	£0	£0	£0	£28,178
								Projected Savings	£3,000	£3,000	£3,000	£3,000	£3,000	£9,000	£6,000	£6,000	£6,000	£0	£0	£0	£42,000
								Actual Savings	£1,124	£823	£179	£220	£212	£9,240	£7,560	£8,820	£0	£0	£0	£0	£28,178

Primary Care - Scriptswitch, workplan and optimisation

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2025/26	Pharmacy Lead	Category		Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Total
Apr-25	Primary Care	ScriptSwitch	Use of Prescribing Decision Support software to generate cost effective switches and formulary compliance	£480,000	£480,000	Rachel Howell	Primary Care	Projected Savings	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£480,000
								Actual Savings	£71,106	£61,688	£55,752	£58,787	£60,387	£50,024	£57,150	£53,011					£467,905
Apr-25	Primary Care	MM Workplan	General Workplan Carry over savings from 24-25 = £315,731	£654,934	£167,500	Rhys Howell	Primary Care	Projected Savings	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£13,958	£167,500
								Actual Savings	£5,837	£17,574	£28,725	£39,036	£49,151	£59,145	£64,757	£71,856					£336,081
								Carry Over Savings	£0	£11,794	£3,804	£25,875	£32,025	£34,744	£81,986	£52,914	£507	£93,855	£52,055	£97,875	£487,434
Apr-25	Primary Care	Medicines Optimisation	Medicines optimisation	£87,521	£82,992	Rhys Howell	Primary Care	Projected Savings	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£82,992
								Actual Savings	-£14	£515	£459	£2,333	£2,809	£3,056	£3,142	£3,341					£15,641
								Carry Over Savings	£0	£70	-£67	£634	-£1,458	£551	£80	-£249	£1,558	£2,727	£1,485	-£802	£4,529
TOTAL				£1,226,984	£735,021			Projected Savings	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£60,874	£730,492
								Actual Savings	£76,929	£79,777	£84,936	£100,156	£112,347	£112,225	£125,049	£128,208	£0	£0	£0	£0	£819,627
								Carry Over Savings	£0	£11,864	£3,737	£26,509	£30,567	£35,295	£82,066	£52,665	£2,065	£96,582	£53,540	£97,073	£491,963
								Total Savings	£76,929	£91,641	£88,673	£126,665	£142,914	£147,520	£207,115	£180,873	£2,065	£96,582	£53,540	£97,073	£1,311,590

Primary Care - individual drugs

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2025/26	Pharmacy Lead	Category		Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Total
Apr 25 to Aug 25	Primary Care	Loss of Exclusivity	Generic Rivaroxaban - Cat M price reduction expected July 24 - Adjusted monthly	£500,000	£500,000	Rhys Howell	Primary Care	Projected Savings	£100,000	£100,000	£100,000	£100,000	£100,000								£500,000
								Actual Savings	£111,788	£116,286	£103,298	£117,102	£115,282								£563,756
Apr 24 to Mar 26	Primary Care	Switch to Prasugrel	Ticagrelor to Prasugrel switch in Cardiology (24 months cost avoidance)	£345,000	£71,875	Rhys Howell	Primary Care	Projected Savings	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£71,875
								Actual Savings	£4,914	£5,191	£5,445	£5,238	£4,257								£25,045
	TOTAL			£845,000	£571,875			Projected Savings	£114,375	£114,375	£114,375	£114,375	£114,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£571,875
								Actual Savings	£116,702	£121,477	£108,742	£122,340	£119,539	£0	£0	£0	£0	£0	£0	£0	£588,800